Logo image of KROS

KEROS THERAPEUTICS INC (KROS) Stock Fundamental Analysis

NASDAQ:KROS - Nasdaq - US4923271013 - Common Stock - Currency: USD

11.02  -0.01 (-0.09%)

After market: 10.9401 -0.08 (-0.73%)

Fundamental Rating

3

KROS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KROS as it has an excellent financial health rating, but there are worries on the profitability. KROS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KROS had negative earnings in the past year.
In the past year KROS has reported a negative cash flow from operations.
In the past 5 years KROS always reported negative net income.
KROS had a negative operating cash flow in each of the past 5 years.
KROS Yearly Net Income VS EBIT VS OCF VS FCFKROS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

The Return On Assets of KROS (-31.34%) is better than 66.25% of its industry peers.
KROS has a Return On Equity of -34.08%. This is in the better half of the industry: KROS outperforms 76.38% of its industry peers.
Industry RankSector Rank
ROA -31.34%
ROE -34.08%
ROIC N/A
ROA(3y)-32.82%
ROA(5y)-45.5%
ROE(3y)-35.98%
ROE(5y)-518.65%
ROIC(3y)N/A
ROIC(5y)N/A
KROS Yearly ROA, ROE, ROICKROS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

1.3 Margins

KROS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KROS Yearly Profit, Operating, Gross MarginsKROS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

KROS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KROS has more shares outstanding
KROS has more shares outstanding than it did 5 years ago.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KROS Yearly Shares OutstandingKROS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 10M 20M 30M
KROS Yearly Total Debt VS Total AssetsKROS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

KROS has an Altman-Z score of 4.43. This indicates that KROS is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of KROS (4.43) is better than 78.69% of its industry peers.
KROS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.43
ROIC/WACCN/A
WACC9.44%
KROS Yearly LT Debt VS Equity VS FCFKROS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M 300M

2.3 Liquidity

KROS has a Current Ratio of 19.03. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
KROS has a Current ratio of 19.03. This is amongst the best in the industry. KROS outperforms 93.96% of its industry peers.
KROS has a Quick Ratio of 19.03. This indicates that KROS is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 19.03, KROS belongs to the best of the industry, outperforming 93.96% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 19.03
Quick Ratio 19.03
KROS Yearly Current Assets VS Current LiabilitesKROS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

KROS shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.25%.
The Revenue has grown by 6410.00% in the past year. This is a very strong growth!
KROS shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -56.77% yearly.
EPS 1Y (TTM)-5.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.02%
Revenue 1Y (TTM)6410%
Revenue growth 3YN/A
Revenue growth 5Y-56.77%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KROS will show a small growth in Earnings Per Share. The EPS will grow by 5.64% on average per year.
KROS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 613.41% yearly.
EPS Next Y-1.8%
EPS Next 2Y2.48%
EPS Next 3Y4.6%
EPS Next 5Y5.64%
Revenue Next Year15528.3%
Revenue Next 2Y296.32%
Revenue Next 3Y1012.85%
Revenue Next 5Y613.41%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
KROS Yearly Revenue VS EstimatesKROS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
KROS Yearly EPS VS EstimatesKROS Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KROS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KROS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KROS Price Earnings VS Forward Price EarningsKROS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KROS Per share dataKROS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y2.48%
EPS Next 3Y4.6%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for KROS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KEROS THERAPEUTICS INC

NASDAQ:KROS (2/21/2025, 8:00:02 PM)

After market: 10.9401 -0.08 (-0.73%)

11.02

-0.01 (-0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)02-27 2025-02-27/amc
Inst Owners102.03%
Inst Owner Change5.37%
Ins Owners0.63%
Ins Owner Change0%
Market Cap446.42M
Analysts80
Price Target30.8 (179.49%)
Short Float %11.02%
Short Ratio2.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.76%
Min EPS beat(2)-8.05%
Max EPS beat(2)0.53%
EPS beat(4)3
Avg EPS beat(4)2.21%
Min EPS beat(4)-8.05%
Max EPS beat(4)11.93%
EPS beat(8)6
Avg EPS beat(8)1.46%
EPS beat(12)8
Avg EPS beat(12)7.24%
EPS beat(16)9
Avg EPS beat(16)4.33%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-34.35%
PT rev (3m)-66.61%
EPS NQ rev (1m)31.08%
EPS NQ rev (3m)26.85%
EPS NY rev (1m)0.28%
EPS NY rev (3m)-0.44%
Revenue NQ rev (1m)33320.4%
Revenue NQ rev (3m)568.31%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-69.73%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 685.75
P/FCF N/A
P/OCF N/A
P/B 0.84
P/tB 0.84
EV/EBITDA N/A
EPS(TTM)-5.21
EYN/A
EPS(NY)-4.94
Fwd EYN/A
FCF(TTM)-3.52
FCFYN/A
OCF(TTM)-3.46
OCFYN/A
SpS0.02
BVpS13.15
TBVpS13.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -31.34%
ROE -34.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.82%
ROA(5y)-45.5%
ROE(3y)-35.98%
ROE(5y)-518.65%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 191.42%
Cap/Sales 335.79%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.03
Quick Ratio 19.03
Altman-Z 4.43
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)251.94%
Cap/Depr(5y)197.59%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-6.02%
EPS Next Y-1.8%
EPS Next 2Y2.48%
EPS Next 3Y4.6%
EPS Next 5Y5.64%
Revenue 1Y (TTM)6410%
Revenue growth 3YN/A
Revenue growth 5Y-56.77%
Sales Q2Q%N/A
Revenue Next Year15528.3%
Revenue Next 2Y296.32%
Revenue Next 3Y1012.85%
Revenue Next 5Y613.41%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-11.56%
EBIT Next 3Y-5.1%
EBIT Next 5YN/A
FCF growth 1Y-105.84%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-105.78%
OCF growth 3YN/A
OCF growth 5YN/A